amsbio (AMS Biotechnology) is a global company founded in 1987, dedicated to accelerating discovery through the provision of cutting-edge life science technology, products, and services. They offer a wide range of high-quality reagents including antibodies, proteins, ELISA kits, cells, tissues, and advanced cell culture solutions like 3D culture systems and exosome research tools. amsbio serves researchers in academic institutions, biotechnology, and pharmaceutical companies, supporting diverse fields such as cancer research, neuroscience, stem cell biology, and drug discovery.
Serves as the central hub for amsbio's global operations, including product development, strategic management, European sales, marketing, customer support, and distribution.
Located within Milton Park, one of Europe's largest science, technology, and business communities, offering state-of-the-art facilities and a dynamic innovation ecosystem.
A collaborative, science-driven, and customer-focused environment dedicated to innovation and providing high-quality solutions to the global research community.
Its location in the UK's 'Golden Triangle' of research (Oxford-Cambridge-London) provides excellent connectivity, access to talent, and opportunities for collaboration within the life sciences sector.
amsbio supports life science research globally through its direct offices in the United Kingdom (Global HQ), United States (Cambridge, MA), Switzerland (Magliaso), and Germany (Hamburg). In addition to these key operational hubs, amsbio maintains an extensive network of distributors across Europe, Asia, Africa, and Oceania, ensuring that researchers worldwide have access to their innovative products, technical expertise, and customer support services.
184 Milton Park
Abingdon
Oxfordshire
United Kingdom
Address: 1035 Cambridge Street, Suite 25A, Cambridge, MA 02141, USA
To provide localized, responsive support and rapid product delivery to the extensive North American life science research market, fostering direct engagement with key opinion leaders and research institutions.
Address: AMS Biotechnology (Europe) Ltd, Riva Viva, CH-6983 Magliaso, Switzerland
To cater to the specific needs of the Swiss and surrounding European life science markets, ensuring efficient service and support, and strengthening amsbio's presence in continental Europe.
Address: AMSBIO GmbH, Peutestrasse 53, 20539 Hamburg, Germany
To enhance amsbio's service capabilities and market penetration within the significant German and Central European life science sectors, providing tailored support to local researchers.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AMSBIO' leadership includes:
AMSBIO has been backed by several prominent investors over the years, including:
As a privately held company, amsbio does not typically publicize detailed executive team changes. No major new hires or exits at the top executive level have been prominently announced in the public domain over the last 12 months.
Discover the tools AMSBIO uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
The most common email format used by amsbio for its employees is the first initial of the first name followed by the full last name, all before the '@amsbio.com' domain. For example, an employee named Jane Smith would likely have an email address like jsmith@amsbio.com.
[first_initial][last]@amsbio.com
Format
jsmith@amsbio.com
Example
85%
Success rate
amsbio.com News • May 28, 2024
AMSBIO has launched a new range of synthetic exosome generation kits, designed to help researchers explore the potential of exosomes in targeted drug delivery. These kits offer advantages in terms of stability, scalability, and modification capabilities compared to naturally derived exosomes....more
amsbio.com News • April 30, 2024
AMSBIO announced an expansion of its organoid biobank, with a specific focus on neurodegenerative diseases. This initiative provides researchers with access to patient-derived 3D organoid models for studying conditions such as Alzheimer's, Parkinson's, and other neurological disorders....more
amsbio.com News • March 26, 2024
AMSBIO is offering advanced tools and services to streamline the high-throughput screening (HTS) of antibody-drug conjugates (ADCs). These solutions aim to accelerate the development of targeted cancer therapies by improving the efficiency and accuracy of ADC candidate selection....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AMSBIO, are just a search away.